Trial reportJournal of general internal medicine2026
Longitudinal Effect of Diabetes Fatalism on Clinical Outcomes and Health-Related Quality of Life in African Americans with Type 2 Diabetes.
Trial report in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundEvidence on diabetes fatalism is largely based on cross-sectional data. This study investigated the longitudinal relationship between diabetes fatalism, clinical outcomes, and health-related quality of life (HRQoL) in African Americans (AA) with type 2 diabetes (T2D) using results from a 12-month RCT.
methodsAA adults (n = 200) with poorly controlled T2D (HbA1c ≥ 8%) were randomly assigned to receive 12 sessions of 30 min/week of technology-intensified diabetes education and skills training or usual care. Glycosylated hemoglobin A1c (HbA1c), systolic and diastolic blood pressure, and the Physical (PCS) and Mental Component Summary (MCS) scores of HRQoL were measured at baseline, 3-,6-,9-, and 12-months. Diabetes fatalism was measured at all time points using validated scoring of the diabetes fatalism scale and its emotional distress subscale. Longitudinal mixed models with random effects were run for each of five outcomes, adjusting for treatment, time, treatment-by-time interaction, and baseline measures.
resultsDiabetes fatalism was negatively associated with MCS over time (β = -0.10, 95%CI [-0.17, -0.03]). Emotional distress subscale scores were positively associated with HbA1c (β = 0.02, 95%CI [0.004,0.04]) and negatively associated with PCS (β = -0.16, 95%CI [-0.27, -0.06]) and MCS (β = -0.23, 95%CI [-0.34, -0.11]).
conclusionsHigher diabetes fatalism scores are associated with lower MCS over time, and higher emotional distress subscale scores are associated with higher HbA1c, lower PCS, and lower MCS over time. This study establishes that the association between diabetes fatalism and diabetes outcomes is persistent over time, and the emotional distress component is particularly detrimental to outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.